Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks Investment Research6/26/2026Neutral
MRKR
Marker Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.01M
P/E Ratio
—
EPS
$-0.55
Beta
1.45
52W High
$2.46
52W Low
$0.81
50-Day MA
$1.43
200-Day MA
$1.37
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Fundamentals
| Revenue (TTM) | $3.55M |
| Gross Profit (TTM) | $-7.96M |
| EBITDA | $-11.79M |
| Operating Margin | -338.50% |
| Return on Equity | -77.00% |
| Return on Assets | -43.60% |
| Revenue/Share (TTM) | $0.20 |
| Book Value | $0.83 |
| Price-to-Book | 1.79 |
| Price-to-Sales (TTM) | 7.90 |
| EV/Revenue | 0.721 |
| EV/EBITDA | -0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -51.00% |
| Shares Outstanding | $16.67M |
| Float | $13.81M |
| % Insiders | 5.49% |
| % Institutions | 23.40% |
Historical Volatility
HV 10-Day
89.64%
HV 20-Day
68.83%
HV 30-Day
64.72%
HV 60-Day
58.35%
HV Rank
17.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.87 target)
3
BuyLatest News
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Zacks Investment Research6/25/2026Positive
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research5/20/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026